- We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic human biology and disease.
- We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
- We are harnessing our foundational ability to characterize specialized human cells and to 3D bioprint functional tissues to create novel in vitro toxicology and liver disease modeling platforms.
- We are striving to change the face of medicine through clinical development of regenerative medicine therapies for treating disease and by enabling translational drug discovery.
|2018 Annual Report||Investor Presentation|
|Recent Investor News|
|Print Page | Email Page | RSS Feeds | Investor Contacts | Financial Tear Sheet|